

Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market 20262031

<https://marketpublishers.com/r/NE84384B972CEN.html>

Date: November 2025

Pages: 223

Price: US\$ 2,999.00 (Single User License)

ID: NE84384B972CEN

Abstracts

The Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market was valued at in and is anticipated to reach by 2031, at a CAGR of 0.2231 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market.

This report delivers a comprehensive overview of the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market. The Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –2031.

Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Scope:

By Diagnostics Segment

Imaging Techniques

Diagnostic Tests

Biopsy

By Therapeutics

Ocaliva

Elafibranor

Cenicriviroc

Selonsertib

Others

By Sales Channel

Hospital Pharmacy

Online Channel

Retail Channel

Key Players

Abbvie Inc.

Cadila Healthcare Limited

Conatus Pharmaceuticals Inc.

Exalenz Bioscience Ltd.

Genfit SA

Gilead Sciences Inc.

Intercept Pharmaceuticals Inc.

Merck & Co., Inc.

Novartis AG

Novo Nordisk A/S

Quest Diagnostics

Shire Plc

Siemens Healthineers

Thermo Fisher Scientific Inc.

WuXi AppTec(List not Exhaustive)

Major Highlights

This report delivers a comprehensive overview of the Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market. The Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing

strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. SCOPE AND METHODOLOGY

- 1.1. Research Methodology
- 1.2. Scope of the Market

2. KEY TRENDS AND DEVELOPMENTS

3. EXECUTIVE SUMMARY

- 3.1. Market Snippet by Diagnostics
- 3.2. Market Snippet by Therapeutics
- 3.3. Market Snippet by Sales Channel
- 3.4. Market Snippet by Region

4. MARKET DYNAMICS

- 4.1. Market impacting factors
 - 4.1.1. Drivers
 - 4.1.2. Restraints
 - 4.1.3. Opportunities
- 4.2. Impact analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's five forces analysis
- 5.2. Value chain analysis
- 5.3. Patent Analysis
- 5.4. Regulatory Analysis

6. COVID-19 ANALYSIS

- 6.1. Analysis of Covid-19 on the Market
 - 6.1.1. Before COVID-19 Market Scenario
 - 6.1.2. Present COVID-19 Market Scenario
 - 6.1.3. After COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid Covid-19
- 6.3. Demand-Supply Spectrum

- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives

7. BY DIAGNOSTICS

- 7.1. Introduction
 - 7.1.1. Market size analysis, and y-o-y growth analysis (%)
 - 7.1.2. By DiagnosticsSegment
- 7.2. Market attractiveness index,

8. BY DIAGNOSTICS SEGMENT

- 8.1. Imaging Techniques *
 - 8.1.1. Introduction
 - 8.1.2. Market Size Analysis, US\$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
- 8.2. Diagnostic Tests
- 8.3. Biopsy

9. BY THERAPEUTICS

- 9.1. Introduction
 - 9.1.1. Market size analysis, and y-o-y growth analysis (%), By Therapeutics Segment
 - 9.1.2. Market attractiveness index, By Therapeutics Segment
- 9.2. Ocaliva *
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis, US\$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
- 9.3. Elafibranor
- 9.4. Cenicriviroc
- 9.5. Selonsertib
- 9.6. Others

10. BY SALES CHANNEL

- 10.1. Introduction
 - 10.1.1. Market size analysis, and y-o-y growth analysis (%), By Sales Channel Segment
 - 10.1.2. Market attractiveness index, By Sales Channel Segment

10.2. Hospital Pharmacy *

10.2.1. Introduction

10.2.2. Market Size Analysis, US\$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029

10.3. Online Channel

10.4. Retail Channel

11. BY REGION

11.1. Introduction

11.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region

11.1.2. Market Attractiveness Index, By Region

11.2. North America

11.2.1. Introduction

11.2.2. Key region-specific dynamics

11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics

11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics

11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel

11.2.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country

11.2.6.1. U.S.

11.2.6.2. Canada

11.2.6.3. Mexico

11.3. South America

11.3.1. Introduction

11.3.2. Key Region-Specific Dynamics

11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics

11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics

11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel

11.3.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country

11.3.6.1. Brazil

11.3.6.2. Argentina

11.3.6.3. Rest of South America

11.4. Europe

11.4.1. Introduction

11.4.2. Key Region-Specific Dynamics

11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics

11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics

11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel

11.4.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country

- 11.4.6.1. Germany
- 11.4.6.2. U.K.
- 11.4.6.3. France
- 11.4.6.4. Spain
- 11.4.6.5. Italy
- 11.4.6.6. Rest of Europe
- 11.5. Asia Pacific
 - 11.5.1. Introduction
 - 11.5.2. Key Region-Specific Dynamics
 - 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics
 - 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
 - 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
 - 11.5.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
 - 11.5.6.1. China
 - 11.5.6.2. India
 - 11.5.6.3. Japan
 - 11.5.6.4. Australia
 - 11.5.6.5. Rest of Asia Pacific
- 11.6. Middle East and Africa
 - 11.6.1. Introduction
 - 11.6.2. Key Region-Specific Dynamics
 - 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics
 - 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
 - 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel

12. COMPETITIVE LANDSCAPE

- 12.1. Competitive scenario
- 12.2. Competitor strategy analysis
- 12.3. Market positioning/share analysis
- 12.4. Mergers and acquisitions analysis

13. COMPANY PROFILES

- 13.1. Abbvie Inc. *
 - 13.1.1. Company Overview
 - 13.1.2. Product Portfolio and Description
 - 13.1.3. Key Highlights
 - 13.1.4. Financial Overview

- 13.2. Cadila Healthcare Limited
- 13.3. Conatus Pharmaceuticals Inc.
- 13.4. Exalenz Bioscience Ltd.
- 13.5. Genfit SA
- 13.6. Gilead Sciences Inc.
- 13.7. Intercept Pharmaceuticals Inc.
- 13.8. Merck & Co., Inc.
- 13.9. Novartis AG
- 13.10. Novo Nordisk A/S
- 13.11. Quest Diagnostics
- 13.12. Shire Plc
- 13.13. Siemens Healthineers
- 13.14. Thermo Fisher Scientific Inc.
- 13.15. WuXi AppTec(*List not Exhaustive*)

14. DATAM INTELLIGENCE

- 14.1. Appendix
- 14.2. About us and services
- 14.3. Contact us

I would like to order

Product name: Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market 20262031

Product link: <https://marketpublishers.com/r/NE84384B972CEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NE84384B972CEN.html>